Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Whitehawk Therapeutics (WHWK) Invested Capital (2018 - 2025)

Historic Invested Capital for Whitehawk Therapeutics (WHWK) over the last 8 years, with Q3 2025 value amounting to $157.2 million.

  • Whitehawk Therapeutics' Invested Capital rose 12821.63% to $157.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $157.2 million, marking a year-over-year increase of 12821.63%. This contributed to the annual value of $52.5 million for FY2024, which is 5011.36% down from last year.
  • Whitehawk Therapeutics' Invested Capital amounted to $157.2 million in Q3 2025, which was up 12821.63% from $172.1 million recorded in Q2 2025.
  • Over the past 5 years, Whitehawk Therapeutics' Invested Capital peaked at $221.7 million during Q1 2025, and registered a low of $35.2 million during Q2 2021.
  • For the 5-year period, Whitehawk Therapeutics' Invested Capital averaged around $119.2 million, with its median value being $124.6 million (2022).
  • As far as peak fluctuations go, Whitehawk Therapeutics' Invested Capital skyrocketed by 21929.57% in 2022, and later crashed by 5011.36% in 2024.
  • Quarter analysis of 5 years shows Whitehawk Therapeutics' Invested Capital stood at $136.7 million in 2021, then grew by 15.89% to $158.4 million in 2022, then crashed by 33.58% to $105.2 million in 2023, then plummeted by 50.11% to $52.5 million in 2024, then skyrocketed by 199.49% to $157.2 million in 2025.
  • Its last three reported values are $157.2 million in Q3 2025, $172.1 million for Q2 2025, and $221.7 million during Q1 2025.